Property:Outcome specification
This is a property of type Text.
S
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Influences on general status: 11 values, 0 to 3 points each
tiredness, appetite, headache, nausea, vomiting, diarrhoea, treatment-related skin symptoms +
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Influences on the intensity of radiation treatment +
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Influence on necessary additional medication due to the side effects of radiotherapy +
Stendell-Hollis et al. (2010): Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors +
Body weight, height and waist and hip circumference were measured following standardised protocols (Khosla & Lowe, 1967; Lean et al., 1995) +
Stendell-Hollis et al. (2010): Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors +
Body composition measurements (mean percentage body fat and lean mass) were assessed using dual energy X-ray absorptiometry (DXA) in accordance with standardised procedures under the direction of a certified radiation technician. +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
PPI-Scale +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Change from baseline to week 6 +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Change from baseline to week 6, measured with a composite score (mean) of questions 29 (Global Health Status) and 30 (QOL) of the EORTC QLQ-C30, twice a week +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Mood, measured daily +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Measured daily +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Measured with the anorexia-cachexia module of the EORTC QLQ-C30 +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Cannabinoid-related toxicity with CannTox module (based on the Drug Reaction Scale of adjectives describing mood, physical feelings, and perceptions of mental or cognitive functions of healthy volunteers under the influence of cannabis);
measured twice a week +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
Measured with functional scales and individual items of the EORTC QLQ-C30 (physical, role, emotional, cognitive, and social functioning; and dyspnea, diarrhea, and financial problems) +